{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:06:49Z","timestamp":1794049609132,"version":"4.8.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.seizure.2026.06.014","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:42:44Z","timestamp":1782492164000},"page":"42-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cannabidiol and epilepsy: therapeutic, mechanistic and clinical significance"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-7463","authenticated-orcid":false,"given":"Nisha","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3801-8057","authenticated-orcid":false,"given":"Preeti","family":"Maan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0954-670X","authenticated-orcid":false,"given":"Jyoti","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Hafizur Rehman","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2026.06.014_bib0001","unstructured":"WHO. Epilepsy. World health organization 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy."},{"key":"10.1016\/j.seizure.2026.06.014_bib0002","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and Epilepsy: definitions proposed by the International league against epilepsy (ILAE) and the International bureau for epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107878","article-title":"Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder","volume":"226","author":"Zamberletti","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.seizure.2026.06.014_bib0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.yebeh.2007.12.019","article-title":"The global burden and stigma of epilepsy","volume":"12","author":"de Boer","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.06.014_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0006","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.seizure.2026.06.014_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2018.1386553","article-title":"A resurging boom in new drugs for epilepsy and brain disorders","volume":"11","author":"Younus","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2026.06.014_bib0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/ecp.10.3","article-title":"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives","volume":"3","author":"Reddy","year":"2010","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0010","first-page":"5165","article-title":"Clinical pharmacology and therapeutics of antiepileptic drugs","volume":"13","author":"Reddy","year":"2020","journal-title":"Int J Pharm Sci Nanotechnol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0011","article-title":"Cannabinoids for epilepsy","volume":"2014","author":"Gloss","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2026.06.014_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","article-title":"Cannabinoids in medicine: a review of their therapeutic potential","volume":"105","author":"Ben Amar","year":"2006","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.seizure.2026.06.014_bib0014","first-page":"1","article-title":"Review on clinical studies with cannabis and cannabinoids 2005-2009","volume":"5","author":"Hazekamp","year":"2010","journal-title":"Cannabinoids"},{"key":"10.1016\/j.seizure.2026.06.014_bib0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/dta.1529","article-title":"Therapeutic potential of cannabinoid medicines","volume":"6","author":"Robson","year":"2014","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.seizure.2026.06.014_bib0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/np960004a","article-title":"The volatile oil composition of fresh and air-dried buds of cannabis sativa","volume":"59","author":"Ross","year":"1996","journal-title":"J Nat Prod"},{"key":"10.1016\/j.seizure.2026.06.014_bib0018","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/092986711794940888","article-title":"Cannabinoids: occurrence and medicinal chemistry","volume":"18","author":"Appendino","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.seizure.2026.06.014_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jps.2600670135","article-title":"Anhydrocannabisativine, a new alkaloid from cannabis sativa L","volume":"67","author":"Elsohly","year":"1978","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/head.13345","article-title":"Medicinal properties of cannabinoids, terpenes, and flavonoids in Cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science","volume":"58","author":"Baron","year":"2018","journal-title":"Headache: J Head Face Pain"},{"key":"10.1016\/j.seizure.2026.06.014_bib0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","article-title":"Chemical constituents of marijuana: the complex mixture of natural cannabinoids","volume":"78","author":"ElSohly","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0022","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0040-4020(65)80064-3","volume":"21","author":"Mechoulam","year":"1965","journal-title":"Tetrahedron"},{"key":"10.1016\/j.seizure.2026.06.014_bib0023","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.seizure.2026.06.014_bib0024","first-page":"175","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/8825358","article-title":"Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: a comprehensive review","volume":"2023","author":"Singh","year":"2023","journal-title":"Behav Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0096","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/molecules26092774","article-title":"Cannabinoids, phenolics, terpenes and alkaloids of Cannabis","volume":"26","author":"Radwan","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.seizure.2026.06.014_bib0097","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(02)00370-3","article-title":"\u03949-Tetrahydrocannabinol regulates Th1\/Th2 cytokine balance in activated human T cells","volume":"133","author":"Yuan","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0098","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1471-4159.2005.03074.x","article-title":"In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta9-tetrahydrocannabinol","volume":"93","author":"Butovsky","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.seizure.2026.06.014_bib0099","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-540-88955-7_8","article-title":"Roles of the endocannabinoid system in learning and memory","author":"Marsicano","year":"2009","journal-title":"Behav Neurobiol Endocannabinoid Syst"},{"key":"10.1016\/j.seizure.2026.06.014_bib0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1189\/jlb.1A1014-479R","article-title":"\u03949-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3\/S100A8","volume":"97","author":"Sido","year":"2015","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0101","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer\u2019s Disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1016\/j.seizure.2026.06.014_bib0102","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-140093","article-title":"The potential therapeutic effects of THC on Alzheimer\u2019s disease","volume":"42","author":"Cao","year":"2014","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.seizure.2026.06.014_bib0103","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","article-title":"\u03949-tetrahydrocannabinol (\u03949-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson\u2019s disease","volume":"38","author":"Carroll","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"De Petrocellis","year":"2012","journal-title":"Acta Physiol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2026.06.014_bib0106","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","article-title":"Cannabis pharmacology: the usual suspects and a few promising leads","volume":"80","author":"Russo","year":"2017","journal-title":"Cannabinoid Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0107","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.seizure.2026.06.014_bib0108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.brainresbull.2021.06.017","article-title":"Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: the role of medial prefrontal cortex 5-HT1A and CB1 receptors","volume":"174","author":"Malvestio","year":"2021","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.seizure.2026.06.014_bib0109","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bpa.2020.06.004","article-title":"Use of cannabidiol (CBD) for the treatment of chronic pain","volume":"34","author":"Urits","year":"2020","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/B978-0-12-817933-8.00052-9","article-title":"Putative effects of cannabidiol in depression and synaptic plasticity","author":"Joca","year":"2021","journal-title":"Neurosci Depress"},{"key":"10.1016\/j.seizure.2026.06.014_bib0111","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00632","article-title":"Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1\u2013CB2 heteroreceptor complexes","volume":"9","author":"Navarro","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0112","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1017\/S1461145713000163","volume":"16","author":"Leonardo","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0113","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.3390\/ijms19071992","article-title":"In vitro model of neuroinflammation: efficacy of cannabigerol, a non-psychoactive cannabinoid","volume":"19","author":"Gugliandolo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0026","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.nurpra.2020.07.022","article-title":"Cannabidiol products: review of the regulatory and clinical considerations","volume":"16","author":"Hawes","year":"2020","journal-title":"J Nurse Pract"},{"key":"10.1016\/j.seizure.2026.06.014_bib0027","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0028","doi-asserted-by":"crossref","unstructured":"G.F. Cannabinoids. Current drug target -CNS & Neurological disorders 2005;4:507\u201330. https:\/\/doi.org\/10.2174\/156800705774322111.","DOI":"10.2174\/156800705774322111"},{"key":"10.1016\/j.seizure.2026.06.014_bib0029","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1523\/JNEUROSCI.4465-07.2008","article-title":"Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic Human hippocampus","volume":"28","author":"Ludanyi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2026.06.014_bib0031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0033","unstructured":"FDA. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210365Orig1s000 APPROVAL LETTER. 2018."},{"key":"10.1016\/j.seizure.2026.06.014_bib0034","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.441","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"101","author":"Reddy","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2026.06.014_bib0035","article-title":"A comparative study on some chemical and biological characteristics of various samples of cannabis resin","author":"Grlic","year":"2026","journal-title":"UNOV Libr Cat"},{"key":"10.1016\/j.seizure.2026.06.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0037","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/BF01922823","article-title":"A comparison of the pharmacological activity in man of intravenously administered 1368-11368-11368-1, cannabinol, and cannabidiol","volume":"29","author":"Perez-Reyes","year":"1973","journal-title":"Experientia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00020","article-title":"In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer\u2019s disease","volume":"8","author":"Watt","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2016.11.020","article-title":"Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy","volume":"70","author":"Allendorfer","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.06.014_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107861","article-title":"A perspective on cannabinoids for treating epilepsy: do they really change the landscape?","volume":"170","author":"Cross","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0042","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P2.277","article-title":"A role of GPR55 in the antiepileptic properties of cannabidiol (CBD) (P2.277)","volume":"90","author":"Whalley","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0043","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.02.009","article-title":"Cannabidiol treatment for refractory seizures in Sturge-Weber Syndrome","volume":"71","author":"Kaplan","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0044","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2026.06.014_bib0045","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S53.004","article-title":"Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors (S53.004)","volume":"90","author":"Whalley","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0047","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0048","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos Trans R Soc B: Biol Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0049","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0050","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0051","doi-asserted-by":"crossref","DOI":"10.1186\/s42238-025-00274-y","article-title":"Beyond the hype: a comprehensive exploration of CBD\u2019s biological impacts and mechanisms of action","volume":"7","author":"Swenson","year":"2025","journal-title":"J Cannabis Res"},{"key":"10.1016\/j.seizure.2026.06.014_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100017","article-title":"Ion channels and GPCRs: cannabidiol actions on disorders of excitability and synaptic E-I ratio","volume":"107","author":"Tsien","year":"2025","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0053","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors","volume":"152","author":"O\u2019Sullivan","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0054","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.imbio.2009.09.007","article-title":"Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease","volume":"215","author":"O\u2019Sullivan","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.seizure.2026.06.014_bib0056","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts \u03b2-amyloid induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces a\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through ppar\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.seizure.2026.06.014_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.seizure.2026.06.014_bib0059","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.bbrc.2020.10.021","article-title":"Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids","volume":"533","author":"Shrader","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seizure.2026.06.014_bib0060","first-page":"47","article-title":"Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations","volume":"38","author":"Espinosa-Jovel","year":"2023","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.seizure.2026.06.014_bib0061","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of Cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.06.014_bib0062","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0063","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","article-title":"A phase II randomized trial to explore the potential for pharmacokinetic drug\u2013Drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy","volume":"34","author":"Ben-Menachem","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2026.06.014_bib0064","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/8825358","article-title":"Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: a comprehensive review","volume":"2023","author":"Singh","year":"2023","journal-title":"Behav Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0066","series-title":"Cannabidiol: science, marketing, and legal perspectives","author":"Wiley","year":"2020"},{"key":"10.1016\/j.seizure.2026.06.014_bib0067","series-title":"EPIDIOLEX\u00ae (cannabidiol) oral solution","year":"2024"},{"key":"10.1016\/j.seizure.2026.06.014_bib0068","article-title":"Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review","volume":"14","author":"Villanueva","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.seizure.2026.06.014_bib0069","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1111\/epi.18622","article-title":"Availability and affordability of cannabinoids for epilepsy treatment across different geographic settings\u2014a survey from the ILAE plant-based therapy task force","volume":"66","author":"Vinayan","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/B978-0-444-52891-9.00065-8","article-title":"Dravet syndrome (severe myoclonic epilepsy in infancy)","volume":"111","author":"Dravet","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0071","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/epi.13889","article-title":"Dravet syndrome and its mimics: beyond SCN1A","volume":"58","author":"Steel","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0072","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.06.014_bib0073","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eplepsyres.2006.01.019","article-title":"Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies","volume":"70","author":"Fujiwara","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.06.014_bib0074","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2026.06.014_bib0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0076","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0077","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/epi.16974","article-title":"Time to onset of cannabidiol treatment effects in Dravet syndrome: analysis from two randomized controlled trials","volume":"62","author":"Madan Cohen","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0078","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2026.06.014_bib0079","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2026.06.014_bib0080","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/epi.16878","article-title":"Time to onset of cannabidiol (CBD) treatment effect in Lennox\u2013Gastaut syndrome: analysis from two randomized controlled trials","volume":"62","author":"Privitera","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0081","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/epi.17199","article-title":"Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: post hoc analysis of randomized controlled phase 3 trial GWPCARE6","volume":"63","author":"Wu","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106988","article-title":"Cannabidiol in treatment of refractory epileptic spasms: an open-label study","volume":"106","author":"Herlopian","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.06.014_bib0083","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.06.014_bib0084","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.seizure.2026.06.014_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for Febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2026.06.014_bib0087","article-title":"Phase 3 trial of cannabidiol (CBD; GWP42003-P) for infantile spasms: open-label extension Phase (GWPCARE7)","year":"2026","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0088","article-title":"A double-blind trial to evaluate efficacy and safety of cannabidiol as an add-on therapy for treatment in refractory epilepsy","year":"2023","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0089","article-title":"Cannabidiol in children with refractory epileptic encephalopathy (CARE-E)","year":"2017","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0090","article-title":"Assessment of adjunctive cannabidiol oral solution (GWP42003-P) in children with tuberous sclerosis complex (TSC), Dravet syndrome (DS), or Lennox-Gastaut syndrome (LGS) who experience inadequately-controlled seizures","year":"2024","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0091","article-title":"Epidiolex\u00ae for anxiety in pediatric epilepsy","year":"2023","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0092","article-title":"Assessment of potential for chronic liver injury in participants treated with epidiolex (Cannabidiol) oral solution","year":"2024","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.seizure.2026.06.014_bib0086","unstructured":"U.S. National Library of Medicine. Home - ClinicalTrials.Gov. Clinicaltrialsgov 2019. https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.seizure.2026.06.014_bib0093","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse events of cannabidiol use in patients with epilepsy","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.seizure.2026.06.014_bib0094","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.06.014_bib0095","unstructured":"NICE. Epilepsies in children, young people and adults NICE guideline. 2022."}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112600186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112600186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:27:08Z","timestamp":1789914428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913112600186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"alternative-id":["S105913112600186X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.06.014","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol and epilepsy: therapeutic, mechanistic and clinical significance","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}